文献速递神经MR

术前MRI指标对弥漫性低级别胶质瘤分子亚型的预后价值

Prognostic Value of Preoperative MRI Metrics for Diffuse Lower-Grade Glioma Molecular Subtypes.
PubMed 文献 · AJNR Am J Neuroradiol · 2020-04-23

该回顾性分析纳入306例低级别胶质瘤患者,由两名神经放射科医生共识分析术前MRI指标,并按分子亚型评估其与总生存期的关联。结果显示,在IDH野生型低级别胶质瘤中,肿瘤大小、受累脑叶数、脑积水、中线移位、边缘及对比增强与总生存期相关;在IDH突变伴1p/19q共缺失亚型中,肿瘤大小和室管膜延伸与总生存期相关。MRI指标可为分子定义的低级别胶质瘤提供预后信息,对IDH野生型预后价值最大。

要点

  • IDH野生型低级别胶质瘤中,肿瘤大小(HR 3.82)、受累脑叶数(HR 1.70)、脑积水(HR 4.43)、中线移位(HR 1.16)、边缘(P=.031)及对比增强(HR 0.34)与总生存期相关。
  • IDH突变伴1p/19q共缺失低级别胶质瘤中,肿瘤大小(HR 2.85)和室管膜延伸(HR 6.34)与总生存期相关。
  • MRI指标对IDH野生型低级别胶质瘤的预后价值最大。

关键影像表现/征象

  • 评估指标包括肿瘤大小、肿瘤位置、受累脑叶数、胼胝体侵犯、脑积水、中线移位、eloquent皮层受累、室管膜延伸、边缘、对比增强和坏死。
  • IDH野生型低级别胶质瘤中,肿瘤大小、受累脑叶数、脑积水、中线移位、边缘及对比增强与总生存期相关。
  • IDH突变伴1p/19q共缺失低级别胶质瘤中,肿瘤大小和室管膜延伸与总生存期相关。

诊断标准与关键数值

  • IDH野生型低级别胶质瘤:肿瘤大小HR 3.82(95%CI 1.94-7.75,P<.001);受累脑叶数HR 1.70(95%CI 1.28-2.27,P<.001);脑积水HR 4.43(95%CI 1.12-17.54,P=.034);中线移位HR 1.16(95%CI 1.03-1.30,P=.013);边缘P=.031;对比增强HR 0.34(95%CI 0.13-0.90,P=.030)。
  • IDH突变伴1p/19q共缺失低级别胶质瘤:肿瘤大小HR 2.85(95%CI 1.06-7.70,P=.039);室管膜延伸HR 6.34(95%CI 1.07-37.59,P=.042)。

临床应用与阅片要点

  • 术前MRI评估低级别胶质瘤时,可关注肿瘤大小、受累脑叶数、脑积水、中线移位、边缘、对比增强及室管膜延伸等指标,并结合分子亚型解读其预后意义。
  • IDH野生型低级别胶质瘤中,对比增强的HR为0.34(95%CI 0.13-0.90,P=.030),提示其与总生存期的关联方向。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: Despite the improved prognostic relevance of the 2016 WHO molecular-based classification of lower-grade gliomas, variability in clinical outcome persists within existing molecular subtypes. Our aim was to determine prognostically significant metrics on preoperative MR imaging for lower-grade gliomas within currently defined molecular categories.

MATERIALS AND METHODS: We undertook a retrospective analysis of 306 patients with lower-grade gliomas accrued from an institutional data base and The Cancer Genome Atlas. Two neuroradiologists in consensus analyzed preoperative MRIs of each lower-grade glioma to determine the following: tumor size, tumor location, number of involved lobes, corpus callosum involvement, hydrocephalus, midline shift, eloquent cortex involvement, ependymal extension, margins, contrast enhancement, and necrosis. Adjusted hazard ratios determined the association between MR imaging metrics and overall survival per molecular subtype, after adjustment for patient age, patient sex, World Health Organization grade, and surgical resection status.

RESULTS: For isocitrate dehydrogenase (IDH) wild-type lower-grade gliomas, tumor size (hazard ratio, 3.82; 95% CI, 1.94-7.75; P < .001), number of involved lobes (hazard ratio, 1.70; 95% CI, 1.28-2.27; P < .001), hydrocephalus (hazard ratio, 4.43; 95% CI, 1.12-17.54; P = .034), midline shift (hazard ratio, 1.16; 95% CI, 1.03-1.30; P = .013), margins (P = .031), and contrast enhancement (hazard ratio, 0.34; 95% CI, 0.13-0.90; P = .030) were associated with overall survival. For IDH-mutant 1p/19q-codeleted lower-grade gliomas, tumor size (hazard ratio, 2.85; 95% CI, 1.06-7.70; P = .039) and ependymal extension (hazard ratio, 6.34; 95% CI, 1.07-37.59; P = .042) were associated with overall survival.

CONCLUSIONS: MR imaging metrics offers prognostic information for patients with lower-grade gliomas within molecularly defined classes, with the greatest prognostic value for IDH wild-type lower-grade gliomas.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Darvishi P, Batchala PP, Patrie JT, et al. Prognostic Value of Preoperative MRI Metrics for Diffuse Lower-Grade Glioma Molecular Subtypes. AJNR Am J Neuroradiol. 2020. PMID: 32327434. doi:10.3174/ajnr.A6511

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。